CD4 and neoplasm: These results suggest an in situ mechanism of NASH with regard to failure on immunotherapies and furthermore identifies a putative strategy to overcome detrimental effects of NASH on CD4 T cell tumor immunity by protecting these cells from ROS-mediated damage.